Three-Year Patient-Reported Outcomes with Bimekizumab in Plaque Psoriasis
Overview
The BE RADIANT phase 3b trial demonstrated that bimekizumab provides sustained improvements in patient-reported outcomes (PROs) over three years in moderate to severe plaque psoriasis. Patients reported significant reductions in symptoms such as itching, skin pain, and scaling, alongside marked improvements in quality of life measured by the Dermatology Life Quality Index (DLQI).
Background
Plaque psoriasis is a chronic inflammatory disease that significantly impairs physical, psychological, and social functioning, affecting patients' quality of life comparably to major medical conditions. Effective treatment requires addressing both clinical severity and patient perceptions, with patient-reported outcomes (PROs) playing a critical role in evaluating treatment impact. Bimekizumab, a monoclonal antibody inhibiting IL-17A and IL-17F, has shown superior efficacy and durability compared to other biologics. The BE RADIANT trial uniquely compared dual IL-17A/F inhibition with IL-17A inhibition alone, focusing on long-term PROs to capture comprehensive patient benefits.
Data Highlights
Outcome Measure
Timepoint
Result
P-SIM Itching = 0 (no symptom)
3 years
High proportion of patients reported no itching
P-SIM Skin Pain = 0
3 years
High proportion of patients reported no skin pain
P-SIM Scaling = 0
3 years
High proportion of patients reported no scaling
DLQI 0-1 (no effect on life)
Up to 3 years
Majority of patients achieved DLQI 0-1
Concurrent PASI and DLQI outcomes
Up to 3 years
Significant proportions achieved PASI 0 and DLQI 0/1
Key Findings
Bimekizumab treatment led to sustained elimination of key psoriasis symptoms (itching, skin pain, scaling) as reported by patients over 3 years.
Majority of patients achieved DLQI scores of 0-1, indicating no impact of psoriasis on quality of life, maintained through 3 years.
Concurrent achievement of clinical clearance (PASI 0 or ≤2) and quality of life improvement (DLQI 0/1) was observed in a significant proportion of patients.
Switching from secukinumab to bimekizumab during the open-label extension maintained or improved PROs, demonstrating bimekizumab’s durable efficacy.
Patient-reported outcomes complemented clinical measures, highlighting the importance of dual IL-17A and IL-17F inhibition in addressing both symptoms and life impact.
Clinical Implications
These findings support the use of bimekizumab as a long-term treatment option for moderate to severe plaque psoriasis, providing durable symptom relief and quality of life improvements from the patient perspective. Incorporating PROs such as P-SIM and DLQI into clinical practice can guide shared decision-making and optimize treatment satisfaction and adherence. Dual inhibition of IL-17A and IL-17F may offer superior benefits compared to IL-17A inhibition alone.
Conclusion
Bimekizumab delivers sustained, meaningful improvements in both clinical and patient-reported outcomes over three years in plaque psoriasis, underscoring its role in comprehensive disease management. Long-term PRO data reinforce its efficacy and impact on patients’ quality of life.
References
BE RADIANT Study Group 2023 -- Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis
by Matthias Augustin, Steven R. Feldman, Richard B. Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H. Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B. Gottlieb
